Literature DB >> 27506115

Buccal mucosal irritation studies of sublingual apomorphine film (APL-130277) in Syrian golden hamsters.

Thierry Bilbault1, Simon Taylor2, Robin Walker3, Starr L Grundy4, Eric J Pappert1, Albert Agro1.   

Abstract

AIM: Determine the potential for cheek pouch buccal mucosa irritation in hamsters following administration of apomorphine hydrochloride film (APL-130277).
METHODS: Three studies were conducted with Syrian golden hamsters. (First study, four hamsters received APL-130277 three times a day [TID] for 7 days. Second study, four hamsters received APL-130277 once a day [QD] for days 1-3, twice a day [BID] for days 4-7 and TID for days 8-21. Third study, 32 hamsters received either a placebo strip or APL-130277-dosed TID for 28 days). For all the studies, the macroscopic appearance of the buccal cavities was evaluated throughout the study. In the third study, all animals were necropsied on day 29, and macroscopic and histopathological examinations were performed.
RESULTS: In the first and second studies, the buccal mucosa of the cheek pouch did not show any signs of irritation. In the third study, administration of APL-130277-dosed TID for 28 consecutive days did not result in observable local irritation of the buccal mucosa.
CONCLUSION: In all the studies, APL-130277 produced no irritation of the cheek pouch buccal mucosa.

Entities:  

Keywords:  APL-130277; Parkinson's disease; apomorphine; buccal mucosal; irritation

Mesh:

Substances:

Year:  2016        PMID: 27506115     DOI: 10.4155/tde-2016-0043

Source DB:  PubMed          Journal:  Ther Deliv        ISSN: 2041-5990


  5 in total

Review 1.  Challenges and trends in apomorphine drug delivery systems for the treatment of Parkinson's disease.

Authors:  Nrupa Borkar; Huiling Mu; René Holm
Journal:  Asian J Pharm Sci       Date:  2017-12-06       Impact factor: 6.598

2.  Poloxamer-188 and d-α-Tocopheryl Polyethylene Glycol Succinate (TPGS-1000) Mixed Micelles Integrated Orodispersible Sublingual Films to Improve Oral Bioavailability of Ebastine; In Vitro and In Vivo Characterization.

Authors:  Nayyer Islam; Muhammad Irfan; Salah-Ud-Din Khan; Haroon Khalid Syed; Muhammad Shahid Iqbal; Ikram Ullah Khan; Amina Mahdy; Mohamed Raafat; Mohammad Akbar Hossain; Sana Inam; Rabia Munir; Memoona Ishtiaq
Journal:  Pharmaceutics       Date:  2021-01-04       Impact factor: 6.321

3.  A deep eutectic-based, self-emulsifying subcutaneous depot system for apomorphine therapy in Parkinson's disease.

Authors:  Jayoung Kim; Yongsheng Gao; Zongmin Zhao; Danika Rodrigues; Eden E L Tanner; Kelly Ibsen; Pradip K Sasmal; Rajasekhar Jaladi; Shanavas Alikunju; Samir Mitragotri
Journal:  Proc Natl Acad Sci U S A       Date:  2022-03-01       Impact factor: 12.779

4.  A Randomized Thorough QT Study of Apomorphine Sublingual Film in Patients With Parkinson's Disease.

Authors:  Fabrizio Stocchi; Elizabeth L Peckham; Maria Francesca De Pandis; Ken Sciarappa; Robert Kleiman; Felix Agbo; C Warren Olanow; David Blum; Bradford Navia
Journal:  Clin Pharmacol Drug Dev       Date:  2022-07-28

5.  Population pharmacokinetic analysis of apomorphine sublingual film or subcutaneous apomorphine in healthy subjects and patients with Parkinson's disease.

Authors:  Felix Agbo; Ryan L Crass; Yu-Yuan Chiu; Sunny Chapel; Gerald Galluppi; David Blum; Bradford Navia
Journal:  Clin Transl Sci       Date:  2021-05-02       Impact factor: 4.689

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.